News
Hosted on MSN24d
Research reveals possible link between protein G3BP1 and amyotrophic lateral sclerosisThese granules protect essential molecules until the stress subsides. The protein G3BP1 plays a key role in this process. Margot Van Nerom, from the Structural Biology Brussels research group ...
Methods Enzymol. 2019;625:13-40. doi: 10.1016/bs.mie.2019.04.012. Epub 2019 May 2. Cyclic GMP-AMP synthase (cGAS) is an innate immune system enzyme responsible for recognition of double-stranded DNA ...
Hosted on MSN6mon
Critical link between protein and ALS disease offers new hopeAt the center of this process is G3BP1, a protein essential for stress granule formation. When stress occurs, G3BP1 transitions from a closed, inactive state to an open, active state, enabling ...
The new result appeared March 23 in The Journal of Cell Biology, in an article entitled, “YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1.” ...
Removing YB-1 decreased levels of one stress granule protein, G3BP1. The team discovered that YB-1 attaches to the mRNA encoding G3BP1 and stimulates the protein's production. To determine the ...
The cGAS-STING pathway facilitates crosstalk between cancer cells and the tumor microenvironment (TME). The activation of cGAS-STING promotes the release and presentation of cancer antigens ...
Cyclic GMP-AMP synthase (cGAS) functions as a foreign DNA sensor, triggering an immune response to pathogens by activating the STING (stimulator of interferon genes) receptor. Shortly after its ...
Cyclic GMP-AMP synthase (cGAS), a critical mediator of innate immune responses, has recently been identified as a potential contributor to cardiac dysfunction. This study was aimed at ...
cGAS activation leads to a type I interferon response, which is implicated in a broad range of diseases, including cutaneous lupus erythematosus, systemic lupus erythematosus, systemic sclerosis ...
Novartis is stepping on the cGAS. Three years after securing an option on an IFM Therapeutics subsidiary, the Swiss drugmaker has accelerated into the deal and paid $90 million upfront for small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results